Denmark-based Freya Biosciences has secured $38m in a Series A funding round to progress the development of women’s reproductive immunotherapies.
Sofinnova Partners and OMX Ventures led the financing round with participation from the Export and Investment Fund of Denmark, Angelini Ventures and CE-Ventures.
The Mike Jafar Family Office, Corundum Systems Biology and Indaco Venture Partners also took part in the round.
Freya will use the proceeds to progress the clinical development of its lead drug candidate, an investigational vaginal microbial immunotherapeutic.
This immunotherapy will be analysed to treat infertility in women with dysbiotic vaginal microbiota who are currently receiving assisted reproductive technology treatment.
The company will also use these funds to advance its multi-omics data science platform, which comprises multiplexed immune biomarker profiling in clinical samples of humans and microbiome sequencing.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Freya Biosciences CEO Colleen Acosta stated: “We are very excited to announce Freya’s Series A fundraise, with the support of this dedicated team of investors.
“Conditions that disproportionately and differently affect women have traditionally been underfunded in proportion to its burden on human health. Freya’s initial focus is on the millions of couples around the world who are struggling with infertility.
“This funding enables us to advance our groundbreaking immunotherapy platform targeting the vaginal microbiota and unlock its therapeutic potential in this area and beyond.”
The latest financing round comes after the company reported positive top-line data from the clinical trial of its lead drug candidate, FB101.
Carried out in Europe, the double-blind, randomised, placebo-controlled trial analysed vaginal microbiome change following vaginal administration of FB101 for three days in women with asymptomatic vaginal tract dysbiosis.
The treatment offered dysbiosis resolution with a quick change to a lactobacillus-dominated vaginal microbiome from dysbiotic. These results were demonstrated to last for more than eight weeks.
